TrivarX Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	1.5yrs
Durata media del Consiglio di amministrazione	2.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

TrivarX non ha un CEO, o non abbiamo dati su di loro.

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Kai Sun	Chief Operating Officer	1.3yrs	AU$173.73k	0.40% A$ 29.3k
Josh Purdy	Public Relations Director	no data	Nessun dato	Nessun dato
Archie Defillo	Chief Medical Officer	no data	Nessun dato	Nessun dato
Massimiliano Grassi	Head of Artificial Intelligence	4.8yrs	Nessun dato	Nessun dato
Anthony Keating	Executive Director	less than a year	Nessun dato	0.24% A$ 17.6k
Stephen Buckley	Company Secretary	1.6yrs	Nessun dato	Nessun dato

1.5yrs

Durata media

Gestione esperta: Il team dirigenziale di TRI non è considerato esperto (durata media 1.5 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Anthony Keating	Executive Director	less than a year	Nessun dato	0.24% A$ 17.6k
Christopher Ntoumenopoulos	Independent Non-Executive Director	1.8yrs	AU$79.79k	1.33% A$ 97.0k
Peter Carlisle	Chairman of Growth & Advocacy Advisory Board	7.4yrs	AU$48.02k	Nessun dato
Patrick Kennedy	Member of Growth & Advocacy Advisory Board	5.3yrs	Nessun dato	Nessun dato
John Mathias	Independent Non-Executive Director	less than a year	Nessun dato	Nessun dato
Michael Phelps	Member of Growth & Advocacy Advisory Board	5.3yrs	Nessun dato	Nessun dato
David Trimboli	Independent Non-Executive Chairman	2.3yrs	AU$97.44k	Nessun dato
Elizabeth Lombardo	Member of Growth & Advocacy Advisory Board	3.2yrs	Nessun dato	Nessun dato

2.7yrs

Durata media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di TRI non è considerato esperto (durata media del mandato 2.7 anni), il che suggerisce un nuovo consiglio.

TrivarX Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

TrivarX Limited, Annual General Meeting, Nov 28, 2024

TrivarX Limited Appoints John H. Mathias II as Non-Executive Director, Effective 1 October 2024

Less than half of directors are independent

Less than half of directors are independent

Medibio Limited, Annual General Meeting, Nov 29, 2023

Medibio Limited, Annual General Meeting, Oct 06, 2023

Recent updates

TrivarX Limited, Annual General Meeting, Nov 28, 2024

TrivarX Limited Appoints John H. Mathias II as Non-Executive Director, Effective 1 October 2024

New major risk - Financial position

Less than half of directors are independent

TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.

Less than half of directors are independent

Medibio Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.006 loss in FY 2022)

Medibio Limited, Annual General Meeting, Oct 06, 2023

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.006 loss in FY 2022)

Less than half of directors are independent

First half 2023 earnings released

Medibio Limited Appoints Christopher Ntoumenopoulos as Director

Less than half of directors are independent

Medibio Limited Announces Resignation of Stephen Mitchley as a Director

Medibio Limited Appoints David Trimboli as the Company's New Non-Executive Chair

Full year 2022 earnings released: AU$0.006 loss per share (vs AU$0.001 loss in FY 2021)

Medibio Limited, Annual General Meeting, Nov 11, 2022

Medibio Limited Appoints Thomas R. Young as CEO

Full year 2022 earnings released: AU$0.006 loss per share (vs AU$0.001 loss in FY 2021)

Medibio Appoints David Trimboli to Its Board of Directors as Non-Executive Director

Medibio Limited Announces Sleep Analysis Depressive Burden Study Clinical Trial Commencement

Medibio Limited Announces Resignation of Claude Solitario as Managing Director

Medibio Limited Announces Executive Changes

Medibio Limited Announces That A DSM-V1 Diagnosis Will Be Included as Primary Comparator for the Purposes of Assessing the Efficacy of Its Depression Algorithms, MEB-001

Less than half of directors are independent

Medibio Limited Appoints Matt Mesnik as Non-Executive Director

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Medibio Limited Appoints Stephen Mitchley as Non-Executive Director

Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.004 loss in FY 2020)

Medibio Limited to Resubmit FDA 510(K) Application for its Sleep Staging Software, MEBbsleep

First half 2021 earnings released: AU$0.001 loss per share (vs AU$0.003 loss in 1H 2020)

Medibio Limited, Annual General Meeting, Mar 24, 2021

Medibio Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.

Medibio Limited Receives CE Mark Approval for Its Sleep Staging Software, MEBsleep

Medibio Limited Commences the Initial Phase of Testing of its Consumer Mental Health App

Medibio Limited Announces US FDA Advises Further Data Needed for Mebsleep Approval

Medibio Limited Signs Global Master License & Services Agreement with Compass Group Plc

Medibio Limited Signs Clinical Trial Agreement with MedBridge Healthcare

Medibio Limited Submits Request for FDA Breakthrough Device Designation

Full year earnings released - AU$0.0044 loss per share

Full year earnings released - AU$0.0044 loss per share

Medibio Limited has completed a Follow-on Equity Offering in the amount of AUD 1.517195 million.

AMMINISTRATORE DELEGATO

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media